Prospective Grant of Exclusive License: Development of Brachyury Tumor Associated Antigens as Cancer Vaccines for Colorectal Cancer, 50425 [2013-20057]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 160 / Monday, August 19, 2013 / Notices
Availability of NIH resources
sufficient to conduct the research
project.
Rockville, MD 20852–3804; Telephone:
(301) 435–5587; Facsimile: (301) 435–
4013; Email: chatterjeesa@od.nih.gov.
Dated: August 13, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2013–20046 Filed 8–16–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Development of Brachyury
Tumor Associated Antigens as Cancer
Vaccines for Colorectal Cancer
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR Part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive patent license to practice
the inventions embodied in the
following U.S. Patents and Patent
Applications to Bavarian Nordic
Immunotherapeutics (‘‘BNIT’’) located
in Mountain View, CA, USA.
Intellectual Property: U.S. Provisional
Patent Application No. 61/701,528
[HHS Ref. No. E–054–2011/0–US–01]
filed September 17, 2012, entitled
‘‘Methods and Compositions for the
Treatment of Cancer,’’ as well as all
international applications, continuation
applications and divisional
applications.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use will be limited to the use of
Licensed Patent Rights for development
of pox virus-based immunotherapeutics
for colorectal cancer.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
September 18, 2013 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
Sabarni K. Chatterjee, Ph.D., M.B.A.
Licensing and Patenting Manager,
Cancer Branch, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
TKELLEY on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:51 Aug 16, 2013
Jkt 229001
Cancer
immunotherapy is a recent approach
where tumor associated antigens
(TAAs), which are primarily expressed
in human tumor cells and not expressed
or minimally expressed in normal
tissues, are employed to generate a
tumor-specific immune response.
Specifically, these antigens serve as
targets for the host immune system and
elicit responses that result in tumor
destruction.
The technology relates to the
development of cancer vaccines
utilizing pox virus vectors encoding
proteins involved in regulating the
epithelial-to-mesenchymal transition
(EMT) during vertebrate development,
as a cancer antigen. Dr. Jeffrey Schlom
et al. at NCI have demonstrated for the
first time that a T-box transcription
factor and a molecule implicated in
EMT, namely the Brachyury protein,
appears to be highly expressed in
metastasizing tumor cells, and could be
a potential target for human T-cell
mediated cancer immunotherapy, such
as for tumors of the lung, intestine,
stomach, kidney, bladder, uterus, ovary,
testis, colon and chronic lymphocytic
leukemia.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within thirty (30) days from the date of
this published notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: August 13, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–20057 Filed 8–16–13; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
50425
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development (NICHD); Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Child Health and
Human Development Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available. A
portion of this meeting will be closed to
the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended for the review and
discussion of grant applications.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the contact person listed below in
advance of the meeting.
Name of Committee: National Advisory
Child Health and Human Development
Council.
Date: September 19, 2013.
Open: September 19, 2013, 8:00 a.m. to
12:00 p.m.
Agenda: The agenda will include: 1)
Update on program issues; 2) Report of the
Director, NICHD; 3) Report of the Scientific
Director, NICHD; and 4) Other business of the
Council.
Closed: September 19, 2013, 1:00 p.m. to
Adjournment.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Center Drive, C-Wing,
Conference Room 6, Bethesda, MD 20892.
Contact Person: Yvonne T. Maddox, Ph.D.,
Deputy Director, Eunice Kenney Shriver
National Institute of Child Health and
Human Development, NIH, 9000 Rockville
Pike MSC 7510, Building 31, Room 2A03,
Bethesda, MD 20892, (301) 496–1848.
Any interested person may file written
comments with the committee by forwarding
the statement to the contact person listed on
this notice. The statement should include the
name, address, telephone number, and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxis, hotel, and airport shuttles,
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
E:\FR\FM\19AUN1.SGM
19AUN1
]]>Agencies
[Federal Register Volume 78, Number 160 (Monday, August 19, 2013)]
[Notices]
[Page 50425]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-20057]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Development of Brachyury
Tumor Associated Antigens as Cancer Vaccines for Colorectal Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
Part 404, that the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an exclusive patent
license to practice the inventions embodied in the following U.S.
Patents and Patent Applications to Bavarian Nordic Immunotherapeutics
(``BNIT'') located in Mountain View, CA, USA.
Intellectual Property: U.S. Provisional Patent Application No. 61/
701,528 [HHS Ref. No. E-054-2011/0-US-01] filed September 17, 2012,
entitled ``Methods and Compositions for the Treatment of Cancer,'' as
well as all international applications, continuation applications and
divisional applications.
The patent rights in these inventions have been assigned to the
government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use will be limited to the use of Licensed Patent Rights
for development of pox virus-based immunotherapeutics for colorectal
cancer.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
September 18, 2013 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated exclusive license should be
directed to: Sabarni K. Chatterjee, Ph.D., M.B.A. Licensing and
Patenting Manager, Cancer Branch, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804; Telephone: (301) 435-5587; Facsimile: (301)
435-4013; Email: chatterjeesa@od.nih.gov.
SUPPLEMENTARY INFORMATION: Cancer immunotherapy is a recent approach
where tumor associated antigens (TAAs), which are primarily expressed
in human tumor cells and not expressed or minimally expressed in normal
tissues, are employed to generate a tumor-specific immune response.
Specifically, these antigens serve as targets for the host immune
system and elicit responses that result in tumor destruction.
The technology relates to the development of cancer vaccines
utilizing pox virus vectors encoding proteins involved in regulating
the epithelial-to-mesenchymal transition (EMT) during vertebrate
development, as a cancer antigen. Dr. Jeffrey Schlom et al. at NCI have
demonstrated for the first time that a T-box transcription factor and a
molecule implicated in EMT, namely the Brachyury protein, appears to be
highly expressed in metastasizing tumor cells, and could be a potential
target for human T-cell mediated cancer immunotherapy, such as for
tumors of the lung, intestine, stomach, kidney, bladder, uterus, ovary,
testis, colon and chronic lymphocytic leukemia.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within thirty
(30) days from the date of this published notice, the NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: August 13, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-20057 Filed 8-16-13; 8:45 am]
BILLING CODE 4140-01-P
